{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The frequency of patients with at least one Grade 3 or greater adverse event that are at least possibly attributable to entinostat during cycle 1 will be summarized by study part, dose level.","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2","id":"OG000","title":"Stratum 1 With 3 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2","id":"OG001","title":"Stratum 1 With 4 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2)","id":"OG002","title":"PK Part With 4 mg/m²"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible enrolled patients.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Frequency of Adverse Events for Entinostat","type":"PRIMARY","unitOfMeasure":"Participants"}